Is high-intensity statin therapy associated with lower statin adherence compared with low- To moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management guidelines

Clinical Cardiology

Volumn 37, Issue 11, 2014, Pages 653-659

  Virani, Salim S ^a,b,c   Woodard, LeChauncy D ^a   Akeroyd, Julia M ^a   Ramsey, David J ^a   Ballantyne, Christie M ^a,c   Petersen, Laura A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOLOGY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CURRENT PROCEDURAL TERMINOLOGY; FEMALE; HEART INFARCTION; HIGH INTENSITY STATIN THERAPY; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; ISCHEMIC HEART DISEASE; LOW TO MODERATE INTENSITY STATIN THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRESCRIPTION; UNSTABLE ANGINA PECTORIS; AGE; ANCESTRY GROUP; BLOOD; CORONARY DISEASE; FACTUAL DATABASE; GOVERNMENT; PERIPHERAL ARTERIAL DISEASE; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AGE FACTORS; AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONTINENTAL POPULATION GROUPS; CORONARY DISEASE; DATABASES, FACTUAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; PERIPHERAL ARTERIAL DISEASE; PRACTICE GUIDELINES AS TOPIC; SEX FACTORS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84912565466     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22343     Document Type: Article

References (24)

1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014;63(25 part B):3024-3025]. J Am Coll Cardiol. 2014;63(25 part B):2889-2934.
2. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
5. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
6. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445.
7. LaRosa JC, Grundy SM,Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
8. Solberg LI, Engebretson KI, Sperl-Hillen JM, et al. Are claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease, and depression. Am J Med Qual. 2006;21:238-245.
9. Woodard LD, Landrum CR, Urech TH, et al. Treating chronically ill people with diabetes mellitus with limited life expectancy: implications for performance measurement. J Am Geriatr Soc. 2012;60:193-201.
10. Ho PM, Magid DJ, Shetterly SM, et al. Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med. 2008;168:271-276.
11. Steiner JF, Koepsell TD, Fihn SD, et al. A general method of compliance assessment using centralized pharmacy records: description and validation. Med Care. 1988;26:814-823.
12. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
13. Vigen R, Shetterly S, Magid DJ, et al. A comparison between antihypertensive medication adherence and treatment intensification as potential clinical performance measures. Circ Cardiovasc Qual Outcomes. 2012;5:276-282.
14. Yang Y, Thumula V, Pace PF, et al. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther. 2009;31:2178-2188.
15. Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25:2303-2310.
16. Virani SS, Woodard LD, Chitwood SS, et al. Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease. Am Heart J. 2011;162:725-732.
17. Virani SS, Woodard LD, Landrum CR, et al. Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines. Am Heart J. 2011;161:1140-1146.
18. Virani SS, Wang D, Woodard LD, et al. Is simple reporting of non-high-density-lipoprotein cholesterol levels associated with improved non-HDL-C goal attainment in primary care setting? J Clin Lipidol. 2012;6:545-552.
19. Woodard LD, Urech T, Landrum CR, et al. Impact of comorbidity type on measures of quality for diabetes care. Med Care. 2011;49:605-610.
20. Petersen LA, Pietz K, Woodard LD, et al. Comparison of the predictive validity of diagnosis-based risk adjusters for clinical outcomes. Med Care. 2005;43:61-67.
21. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
22. Wenger NK. Prevention of cardiovascular disease: highlights for the clinician of the 2013 American College of Cardiology/American Heart Association guidelines. Clin Cardiol. 2014;37:239-251.
23. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088-2097.
24. Rodriguez F, Cannon CP, Steg PG, et al; REACH Registry Investigators. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry. Clin Cardiol. 2013;36:721-727.